Yasuo Koishihara

This inventor holds 10 USPTO granted patents and 1 EPO patent. Top assignees: Chugai Seiyaku Kabushiki Kaisha, University College London. Active years: 2003-2014.

USPTO Granted Patents = 10

% Patents Active = 60.0

EPO Patents = 1

Average Co-Inventor Count = 3.2

ph-index = 3

Forward Citations = 39(Granted Patents)

Location History:

Gotemba, JP (2005)
Gotenba, JP (2003 - 2011)
Tokyo, JP (2010 - 2013)
Chuo-ku, JP (2014)

Company Filing History:

10 out of 985

Chugai Seiyaku Kabushiki Kaisha

patents

1 out of 119

University College London

patents

where one patent can have more than one assignee

Years Active: 2003-2014

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8652839 - HM1.24—utilizing cancer vaccines (2014-02-18),

2. 8603481 - Therapeutic agents for solid tumors (2013-12-10),

3. 7892543 - Reshaped human anti-HM 1.24 antibody (2011-02-22),

4. 7790152 - Enhancer for antibody to lymphocytic tumors (2010-09-07),

5. 7776612 - Method of quantifying antigen expression (2010-08-17),

6. 6908750 - Gene encoding HM1.24 antigen protein and promoter thereof (2005-06-21),

7. 6900052 - Method of culturing cells (2005-05-31),

8. 6699974 - Reshaped human anti-HM 1.24 antibody (2004-03-02),

9. 6613546 - Gene encoding HM1.24 antigen protein and promoter thereof (2003-09-02),

10. 6503510 - Remedies for lymphocytic tumors (2003-01-07),

Title: Yasuo Koishihara: Innovator in Cancer Vaccine Development

Introduction

Yasuo Koishihara is a prominent inventor based in Gotenba, Japan. He has made significant contributions to the field of cancer research, particularly in the development of innovative cancer vaccines. With a total of 10 patents to his name, Koishihara's work has the potential to impact the treatment of solid tumors and improve patient outcomes.

Latest Patents

Among his latest patents, one notable invention is the HM1.24 cancer vaccine. This vaccine contains an antigen-specific dendritic cell pulsed by an HM1.24 protein, HM1.24 peptide, or is transduced with an HM1.24-encoding gene, or HM1.24 protein-encoding DNA or RNA. Another significant patent involves therapeutic agents for solid tumors, which comprise an antibody that specifically binds to a protein with the amino acid sequence represented by SEQ ID NO:2 or an antibody fragment that maintains the antibody activity.

Career Highlights

Throughout his career, Yasuo Koishihara has worked with esteemed organizations such as Chugai Seiyaku Kabushiki Kaisha and University College London. His experience in these institutions has allowed him to collaborate with leading experts in the field and further his research endeavors.

Collaborations

Koishihara has collaborated with notable colleagues, including Masaaki Kosaka and Toshihiko Ohtomo. These partnerships have contributed to the advancement of his research and the development of innovative solutions in cancer treatment.

Conclusion

Yasuo Koishihara's contributions to cancer vaccine development highlight his dedication to improving healthcare through innovation. His patents and collaborations reflect a commitment to advancing medical science and providing new hope for patients battling cancer.